GLP-1 drugs have revolutionized obesity treatment. However, it’s time to concede something that pharma would rather not: Pharma completely underestimated the effort required to retain patients on these drugs. This isn’t an efficacy problem. The clinical data for Wegovy, Zepbound, et al have been phenomenal. The issue is what happens after the prescription is written. Pharma invested heavily in awareness, consumer demand, physician detailing, and branding. It did not – and does not – invest nearly enough in the patient-support and physician education infrastructure needed to keep millions of people on these drugs. Those shortcomings are becoming evident in the real world.
The discontinuation problem is enormous
A 2025 JAMA Network Open study followed more than 125,000 adults with overweight or obesity who started a GLP-1 therapy. Among patients without type 2 diabetes, 64.8% had discontinued within one year and 84.4% within two years. Another large real-world analysis found that patients with obesity alone had a 12-month discontinuation rate of 50.3%, substantially higher than patients with diabetes.
More recent research paints an equally troubling picture. A large claims analysis of adults with overweight or obesity without diabetes found that only 24.5% remained persistent on GLP-1 therapy at 12 months.
Obvious reasons include: Cost. Insurance coverage. Drug availability. Benefits changes. Patient expectations. And AEs. Pharma doesn’t control all those areas. But they could have done a better job at managing physician and patient expectations about what GLP-1 treatment actually entails.
Writing the prescription was never going to be enough
GLP-1s are not your run-of-the-mill “take your pill and come back in six months” therapies. These drugs require ongoing management. Patients need to know about titration. They need to have realistic expectations about how much weight they can lose. They need to know what may happen as doses are increased. They need to know which gastrointestinal effects are common and when to seek medical attention. And they need access to someone when things don’t go as expected. Let’s use Zepbound as an example.
Gastrointestinal adverse reactions were reported in 56% of patients treated with Zepbound in pooled clinical trials compared to 30% on placebo. Nausea, diarrhea, and vomiting were most frequent during dose escalation, and then generally improved over time. This is a key point. If you’re a patient who isn’t properly prepared for nausea when you increase your dose, you might think: “This drug just isn’t working for me.” But if you understand that gastrointestinal side effects are common during dose escalation and may improve over time, you’ll have a very different reaction. You have two very different patient experiences. Education can help ensure you have the latter.

Doctors weren’t prepared for the avalanche
Pharma also got the physician-education challenge wrong. Demand for GLP-1s quickly expanded beyond endocrinologists and obesity specialists. PCPs suddenly found themselves on the front lines of obesity treatment. But treating obesity is complex. Physicians needed practical advice regarding titration, adverse event management, nutrition, patient expectations, treatment interruptions, and restarting therapy. They also needed these answers quickly. Something PCPs have little time for. Pointing doctors to the prescribing information document, a patient brochure, and the manufacturer’s website wasn’t going to cut it. Docs needed scalable clinical education and practical tools they could use within their practice.
Pharma confused access support with patient support
This might have been pharmaceutical companies’ single largest strategic blunder. For years, Pharma’s approach to “patient support” has focused on ensuring that the prescription is filled: Prior authorization. Copay cards. Savings programs. Reimbursement navigation. Etc. Those programs are important. But starting a patient on therapy is the easy part.
The real challenge is: How do we keep this patient on therapy for years? Doing that requires a completely different infrastructure. Patients may need onboarding, education on expectations, proactive follow-up on topics like dose escalation, nutrition, and understanding potential adverse events, and easy access to qualified healthcare professionals if problems arise. The patient journey starts well before they pick up that prescription at the pharmacy.
Pharma allowed social media to market their drugs
The social media buzz around GLP-1 drugs was enormous and continues today, both positive and negative. With distrust in pharma at an all-time high, people are more likely to trust other people on social media, but in an analysis I conducted for a client, 90% of claims on social media were false or had poor results. Pharma seems to take a risk-averse approach to social media rather than engaging the community with real, data-driven posts.
I understand the regulatory restraints on using social media, but posts from thought leaders on using GLP-1s and when to ask for them would have been great.
The industry should have seen this coming
Clinical trials are conducted in closed systems. Patients are brought back for monitored visits and follow-up. Clinical practice doesn’t happen like that. You or your patient may walk into a doctor’s office, get a prescription during a 15-minute primary care appointment, watch a 3-minute instructional video on injection technique, and leave. Two weeks later, you begin feeling nauseous. Who do you reach out to? Your doctor? Your pharmacist? The drug company? Facebook weight loss group? TikTok? When your patients are using social media to figure out how to take a prescription medication, we have failed somewhere.
Discontinuation should have become one of Pharma’s most important KPIs
Pharma loves to focus on prescriptions. New-to-brand prescriptions. Total prescriptions. Market share. Patient starts. But perhaps for chronic GLP-1 therapy one of the most critical numbers should be: How many patients are still on therapy 12 months later?
Emerging data suggest gastrointestinal adverse events play a huge role. In that massive JAMA study of 125,474 patients, moderate or severe GI adverse events were independently significantly associated with increased discontinuation rates. If so, that should drive a fundamental shift in commercial strategy. Landing a patient who quits several months after initiating therapy may not be a successful patient acquisition. It may be a failed patient journey.
What should Pharma do now?
GLP-1 makers need to think and act less like Big Pharma marketers and more like chronic-care companies. That means investing much more heavily in the ecosystem around the drug: physician education, patient onboarding, expectation setting, proactive support around titration, better AE education, nutrition counseling, etc. And GLP-1 makers need to study drop-off as rigorously as they study new prescriptions. Why did they discontinue? When did they discontinue? What happened right before they discontinued? Was it cost, side effects, mismatched expectations, access to care or lack of clinical support? These are no longer just epidemiological questions. They are commercial ones, too.
The next GLP-1 battle isn’t acquisition. It’s persistence.
Phase 1 of the GLP-1 wars has been focused on demand. Phase 2 will be about access. But the long-term battle may ultimately be about persistence. Winners may not be defined by who writes the most prescriptions. They may be determined by who builds an ecosystem that helps patients stay successfully treated. Pharma created fantastic medicines. But along the way, it seems they thought the medicine would do all the heavy lifting.
Newly released real-world persistence data show that’s not the case. A blockbuster drug without a blockbuster patient-support plan is an incomplete drug. Looks like we’re learning that lesson the hard way (and expensively) with GLP-1s.

